Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Mar 1;288(9):6542-51.
doi: 10.1074/jbc.M112.429084. Epub 2013 Jan 18.

The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation

Fabien Wauquier  1 , Claire Philippe, Laurent Léotoing, Sylvie Mercier, Marie-Jeanne Davicco, Patrice Lebecque, Jérôme Guicheux, Paul Pilet, Elisabeth Miot-Noirault, Vincent Poitout, Thierry Alquier, Véronique Coxam, Yohann Wittrant
Affiliations

The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation

Fabien Wauquier et al. J Biol Chem. .

Abstract

The mechanisms linking fat intake to bone loss remain unclear. By demonstrating the expression of the free fatty acid receptor G-coupled protein receptor 40 (GPR40) in bone cells, we hypothesized that this receptor may play a role in mediating the effects of fatty acids on bone remodeling. Using micro-CT analysis, we showed that GPR40(-/-) mice exhibit osteoporotic features suggesting a positive role of GPR40 on bone density. In primary cultures of bone marrow, we showed that GW9508, a GRP40 agonist, abolished bone-resorbing cell differentiation. This alteration of the receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation occurred via the inhibition of the nuclear factor κB (NF-κB) signaling pathway as demonstrated by decrease in gene reporter activity, inhibitor of κB kinase (IKKα/β) activation, inhibitor of κB (IkBα) phosphorylation, and nuclear factor of activated T cells 1 (NFATc1) expression. The GPR40-dependent effect of GW9508 was confirmed using shRNA interference in osteoclast precursors and GPR40(-/-) primary cell cultures. In addition, in vivo administration of GW9508 counteracted ovariectomy-induced bone loss in wild-type but not GPR40(-/-) mice, enlightening the obligatory role of the GPR40 receptor. Then, in a context of growing prevalence of metabolic and age-related bone disorders, our results demonstrate for the first time in translational approaches that GPR40 is a relevant target for the design of new nutritional and therapeutic strategies to counter bone complications.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
GPR40−/− mice exhibit an osteoporotic phenotype. A, micro-CT analysis with corresponding images of left femurs from wild-type (WT) and GRP40−/− mice (males; 16 weeks old mice; n = 11/group; BV/TV, bone volume/total volume; Tb.N, trabecular number; Tb.Sp, trabecular spaces; Tb.Th, trabecular thickness). B, bone mineral density. C, Western blot analysis of GPR40 expression in bone (tibia). Error bars represent standard deviation (±S.D.); *, p < 0.05.
FIGURE 2.
FIGURE 2.
GW9508 inhibits RANKL-induced osteoclast differentiation in primary cell cultures obtained from mouse bone marrow tissues. A and B, TRACP staining: wild-type (WT) versus GPR40−/− mice (KO). Magnification, ×10 (Zeiss). Osteoclast differentiation was induced by murine recombinant RANKL (50 ng/ml). DMSO was used as a vehicle. GPR40 agonist GW9508 was used at either 10 or 50 μm (GW10 or GW50). C, osteoclast marker expression analyzed by real-time RT-PCR. Error bars represent standard deviation (±S.D.); *, p < 0.05.
FIGURE 3.
FIGURE 3.
GW9508 inhibits RANKL-induced osteoclastogenesis in RAW264.7 cell cultures. A, RT-PCR and Western blot analysis. Cells were invalidated for GPR40 expression (Sh) or transfected with a nontargeting vector (SCR). B, TRACP enzymatic activity. Osteoclast differentiation was induced by murine recombinant RANKL (50 ng/ml). DMSO was used as a vehicle. GPR40 agonist GW9508 was used at either 10 or 50 μm (GW10 or GW50). C, osteoclast marker expression analyzed by real-time RT-PCR. GPR40 agonist GW9508 was used at either 10 or 50 μm. *, p < 0.05. D, XTT cell viability assay. *, p < 0.05 versus DMSO control; error bars represent standard deviation (±S.D.).
FIGURE 4.
FIGURE 4.
GW9508 inhibits RANKL-induced signaling pathways in RAW264.7 cell cultures. A, Western blot analysis of IkBα and IKKα/β phosphorylation. B, NF-κB-dependent luciferase assay. DMSO was used as a vehicle. GPR40 agonist GW9508 was used at 50 μm (GW50). Relative light units were measured at 6 and 24 h after incubation and reported to total protein content. C, NFATc1 expression analyzed by real-time RT-PCR in cells invalidated for GPR40 expression (Sh) or transfected with a nontargeting vector (SCR). *, p < 0.05. DMSO was used as a vehicle. GPR40 agonist GW9508 was used at either 10 or 50 μm (GW10 or GW50). Error bars represent standard deviation (±S.D.).
FIGURE 5.
FIGURE 5.
GPR40 agonist as a protective agent against in vivo OVX-induced bone loss. A, bone microarchitecture (females; OVX, ovariectomy; Sh, Sham-operated; 14-week-old mice; n = 7 per group; BV/TV, bone volume/total volume; Tb.N, trabecular number; Tb.Sp, trabecular spaces; Tb.Th, trabecular thickness). Mice received either DMSO as vehicle or GPR40 agonist GW9508 (8 mg/kg of body weight: GW). B, representative bone tissue marker expression analyzed by TLDA on whole tibiae (Applied Biosystems 7900HT real-time PCR system). Tissues were collected from OVX or Sham-operated mice that received either DMSO as vehicle or GPR40 agonist GW9508 (8 mg/kg of body weight: GW). Different letters are attributed to significantly different groups (p < 0.05); error bars represent standard deviation (±S.D.).
FIGURE 6.
FIGURE 6.
GW9508 protective effect on bone is dependent on GPR40 expression. A, food intake. Consumption was analyzed weekly throughout the protocol. B, mouse body weight. Mice were weighed every week throughout the experimental period. C and D, EchoMRI body composition analysis. Mice received either DMSO as vehicle or GPR40 agonist GW9508 (8 mg/kg of body weight: GW). E, bone mineral density (females; OVX, ovariectomy; SH, Sham-operated; 14-week-old mice; n = 7/group; wild-type (WT) versus GPR40−/− mice). Different letters are attributed to significantly different groups (p < 0.05); error bars represent standard deviation (±S.D.).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ono K., Kaneko H., Choudhary S., Pilbeam C. C., Lorenzo J. A., Akatsu T., Kugai N., Raisz L. G. (2005) Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J. Bone Miner. Res. 20, 23–29 - PubMed
    1. Tsutsumi R., Xie C., Wei X., Zhang M., Zhang X., Flick L. M., Schwarz E. M., O'Keefe R. J. (2009) PGE2 signaling through the EP4 receptor on fibroblasts upregulates RANKL and stimulates osteolysis. J. Bone Miner. Res. 24, 1753–1762 - PMC - PubMed
    1. Laneuville O., Breuer D. K., Xu N., Huang Z. H., Gage D. A., Watson J. T., Lagarde M., DeWitt D. L., Smith W. L. (1995) Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2: formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from α-linolenic acid. J. Biol. Chem. 270, 19330–19336 - PubMed
    1. Raisz L. G., Alander C. B., Simmons H. A. (1989) Effects of prostaglandin E3 and eicosapentaenoic acid on rat bone in organ culture. Prostaglandins 37, 615–625 - PubMed
    1. Corwin R. L. (2003) Effects of dietary fats on bone health in advanced age. Prostaglandins Leukot. Essent. Fatty Acids 68, 379–386 - PubMed

Publication types

MeSH terms